関連する実験動画

Updated: Sep 9, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

新型プロトアピゲノンアナログWYC-241の合成と抗がん生物学的評価

Pei-Yi Chu¹, Yi-Cheng Pan¹, Wei-Yu Hsu¹

¹Chinese Medicine Research and Development Center, China Medical University Hospital Taichung 404332 Taiwan jinrain.tw@gmail.com.

RSC medicinal chemistry

|September 2, 2025

まとめ

研究者らは,強力な抗がん作用を示す新型原アピゲノンの WYC-241 を開発した. この化合物はマウスの腫瘍増殖を効果的に抑制し新しいがん治療法としての可能性を示しています

科学分野:

自然製品化学
薬剤化学
癌生物学

背景:

フラボノイドプロトアピゲノンのような天然製品は抗癌薬の発見に不可欠です
前回のWYC-0209の合成では,プロトアピゲノンの誘導体が強化された抗癌特性を示した.

研究の目的:

プロトアピゲノンの誘導体を最適化して,抗がん治療の有効性を向上させる.
ナフタレンリングの改変による新しい WYC-0209 誘導体の合成と評価.

主な方法:

18種類のWYC-0209を合成し,その抗がん性について評価した.
A549肺がん細胞に対するWYC-241の効果の評価,増殖,移動,細胞死経路 (ネクロス,アポトーシス) を含む.
マウスにおける腫瘍増殖抑制の研究と,薬剤のような特性に対するADMETの in silico分析.

主要な成果:

WYC-241と呼ばれる2つのイソペンチル置換のサイドチェーンを持つ誘導体は,優れた細胞毒性を示した.
WYC-241は,A549細胞の増殖と移動を有意に抑制し,活性酸素種 (ROS) の増加とPI3K/ AKT経路の阻害によってネクロスとアポトーシスを誘導しました.
WYC-241はマウスの腫瘍増殖を大幅に抑制し,シリコ分析に基づいて薬剤のような特性を示した.

結論:

WYC-241は非常に有望な抗がん剤であり,強力な効能と好ましい薬剤のような特性を持っています.
この研究は,新しい抗がん療法としてのWYC-241の将来の開発と最適化のための強力な基盤を提供します.

さらに関連する動画

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

関連する概念動画

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...